medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 5

<< Back Next >>

Ann Hepatol 2017; 16 (5)

Waiting-Time and Quality of Care Deserved to Patients with Early Stage Hepatocellular Carcinoma Undergoing RFA Treatment

Soresi M, Licata A, Giannitrapani L, Montalto G

Language: English
References: 16
Page: 699-701
PDF size: 105.22 Kb.


Text Extraction

Hepatocellular carcinoma (HCC) accounts for 70%- 90% of primary liver cancers, and is the fifth most common cancer in Western countries.1 HCC is a rapidly evolving tumor, with difficult management and with a survival ‹ 15% at 5 years despite new diagnostic technologies and new therapies have led to an improvement in patient outcomes. Several factors contribute to poor prognosis: the presence of a coexisting liver cirrhosis which limits responsiveness to systemic chemotherapy, the frequent association with comorbidities, the often delay of diagnosis. In this respect, to reduce diagnosis delay, international scientific societies such as the European Association for the Study of the Liver (EASL), the Japan Society of Hepatology (JSH) and the American Association for the Study of Liver Diseases (AASLD) proposed screening schedules for patients at risk of developing hepatocellular carcinoma.


REFERENCES

  1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365(12): 1118-27.

  2. Brahmania M, Ahmed O, Kelley M, Kowgier M, Khalili K, Beecroft R, Renner EL, et al. Wait Time for Curative Intent Radio Frequency Ablation is Associated with Increased Mortality in Patients with Early Stage Hepatocellular Carcinoma. Annals of Hepatology 2017; 16: 765-71.

  3. Weis S, Franke A, Mössner J, Jakobsen JC, Schoppmeyer K. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2013; 12: 1-73.

  4. Yun YH, Kim YA, Min YH, Park S. The influence of hospital volume and surgical treatment delay on long-term survival after cancer surgery. Ann Oncol 2012; 23: 2731-7.

  5. Helewa RM, Turner D, Park J, Wirtzfeld D, Czaykowski P, Hochman D, Singh H, et al. Longer waiting times for patients undergoing colorectal cancer surgery are not associated with decreased survival. J Surg Oncol 2013; 108(6): 378-84.

  6. Jooste V, Dejardin O, Bouvier V, Arveux P, Maynadie M, Launoy G, Bouvier AM. Pancreatic cancer: Wait times from presentation to treatment and survival in a population-based study. Int J Cancer 2016; 139(5): 1073-80.

  7. Stec AA, Coons BJ, Chang SS, Cookson MS, Herrell SD, Smith JA Jr, Clark PE, et al. Waiting time from initial urological consultation to nephrectomy for renal cell carcinoma: Does it affect survival? J Urol 2008; 179: 2152-7.

  8. Symonds RP. Cancer biology may be more important than diagnostic delay. BMJ 2002; 325(7367): 774.

  9. Umezu T, Shibata K, Kajiyama H, Yamamoto E. Prognostic factors in stage IA-IIA cervical cancer patients treated surgically: Does the waiting time to the operation affect survival? Arch Gynecol Obstet 2010; 285: 493-7.

  10. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: A systematic review. Lancet 1999; 353: 1119-26.

  11. Pacifico MD, Pearl RA, Grover R. The UK Government twoweek rule and its impact on melanoma prognosis: An evidence- based study. Ann R Coll Surg Engl 2007; 89: 609-15.

  12. Ramos M, Esteva M, Cabeza E, Campillo C, Llobera J, Aguiló A. Relationship of diagnostic and therapeutic delay with surviva in colorectal cancer: a review. Eur J Cancer 2007; 43: 2467-8.

  13. Kulkarni GS, Urbach DR, Austin PC, Fleshner NE, Laupacis A, et al. Longer wait times increase overall mortality in patients with bladder cancer. J Urol 2009; 182: 1318-24.

  14. Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Fox R, Yeo W, et al. Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. Br J Cancer 2017; 116(4): 441-7.

  15. Radunz S, Treckmann J, Baba HA, Best J, Müller S, Theysohn JM, Paul A, et al. Long-Term Outcome After Liver Transplantation for Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment. Ann Transplant 2017; 22: 215-21.

  16. Beppu T, Nakagawa S, Nitta H, Okabe H. The Number of Positive Tumor Marker Status Is Beneficial for the Selection of Therapeutic Modalities in Patients with Hepatocellular Carcinoma. J Clin Transl Hepatol 2017; 5(2): 165-8.




2020     |     www.medigraphic.com